Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment

Author： Hubalek Michael  

Publisher： Springer Publishing Company

ISSN： 0043-5341

Source： Wiener Medizinische Wochenschrift, Vol.160, Iss.19-20, 2010-11, pp. : 506-512

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer

By  

Oncology, Vol. 88, Iss. 2, 2014-10 ,pp. : 76-85

Karger

Access to resources Recommend Favorite

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

By  

Oncology Research and Treatment, Vol. 38, Iss. 6, 2015-05 ,pp. : 291-298

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite